pifithrin has been researched along with 22q11.2 Deletion Syndrome in 1 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " Half dosage of this gene in humans causes most of the features of the DiGeorge or Velocardiofacial syndrome phenotypes, including aortic arch and cardiac outflow tract abnormalities." | 1.40 | p53 Suppression partially rescues the mutant phenotype in mouse models of DiGeorge syndrome. ( Baldini, A; Caprio, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caprio, C | 1 |
| Baldini, A | 1 |
1 other study available for pifithrin and 22q11.2 Deletion Syndrome
| Article | Year |
|---|---|
p53 Suppression partially rescues the mutant phenotype in mouse models of DiGeorge syndrome.
Topics: Animals; Arteries; Benzothiazoles; Branchial Region; Chromatin; Crosses, Genetic; DiGeorge Syndrome; | 2014 |